UPDATE: InterMune (ITMN) to Divest ActImmune for $55M in Cash, Plus Two-Year Royalty Stream

Article Stock Quotes (1) Comments (0)

(Updated - May 21, 2012 4:55 PM EDT)

InterMune (Nasdaq: ITMN) reached a definitive agreement with Vidara Therapeutics International Limited (Vidara) to sell its rights to Actimmune® (interferon gamma-1b) in a cash transaction valued at $55 million plus a two-year royalty stream.

The transaction with Vidara is expected to close during the second quarter of 2012, subject to satisfaction of certain closing conditions. Locust Walk Partners LLC is acting as exclusive financial advisor to InterMune in connection with the transaction.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: Sprint (S) to Raise Offer for Clearwire (CLWR) - DJ
• InterOil (IOC) Enters negotiations with ExxonMobil (XOM) on Development Of The Elk And Antelope Resource
• Clearwire Corporation (CLWR) Ramps, Trades Above $3.40/ Share

Create E-mail Alert Related Categories

Mergers and Acquisitions

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?